Show results for
Refine by
Cancer Detection Suppliers Serving Monaco
66 companies found
based inNew York, NEW YORK (USA)
Acuamark Diagnostics develops technology which allows for highly accurate screening of blood to detect cancer markers at the early cancer stages, before the cancer becomes untreatable. Backed by a highly experienced team of scientific and business ...
The vast majority of cancer cases are detected at stage III or beyond, resulting in poor cancer survival of ~50% in the aggregate. Cancer cases are forecasted to reach 25M per ...
based inTaipei City, TAIWAN
At LabTurbo Biotech Corporation, we devote full effort to the research, manufacture and provision of fast, accurate, automated and high throughput gene detection systems and kits. We focus on the development of multi-target detection panels with ...
based inArnhem, NETHERLANDS
Soteria Medical B.V. is a Spin Off from Radboudumc in Nijmegen, The Netherlands. Many years of development and clinical research have resulted in a new approach to perform MRI guided interventions by utilizing a robotic device, which is fully ...
Prostate cancer is the most common cancer, other than non-melanoma skin cancer, and the second leading cause of cancer-related death in men in the United States. Prostate cancer incidence rates rose dramatically in the late 1980s, when screening ...
based inMilan, ITALY
Tethis S.p.A is based in Milan, Italy, and is developing a novel workflow to bring liquid biopsy in the clinical practice for the precise management of cancer. Tethis’ technology points to standardization of the blood sample preparation to provide ...
based inJena, GERMANY
As a biotechnology company, we at oncgnostics GmbH have been working on the diagnosis of cancer on a molecular biological basis since 2012. Our cancer tests are used in early cancer detection and diagnosis.Our first product, GynTect®, was developed ...
based inSan Diego, CALIFORNIA (USA)
CureMetrix is committed to the advancement of technology that will improve cancer survival rates worldwide. Our research is focused on leveraging artificial intelligence and deep learning to develop the next generation of medical image analysis ...
cmDensity An investigational, artificial intelligence- based triage software that helps radiologists classify density accurately and ...
based inAmsterdam, NETHERLANDS
Self-screen has a long history and track record in translational HPV related science. The company was founded in 2008 to advance the implementation of scientific discoveries in the field of HPV related cancer screening into routine practice. Our ...
The QIAsure Methylation Test is intended to be used as a triage test for women with a positive HPV DNA test or for women with ASC-US cytology to identify those women who need to be referred for colposcopy. The QIAsure Methylation Test is a multiplex ...
based inGuro-gu, SOUTH KOREA
We provide diagnostic solutions throughout the cancer treatment cycle from early cancer diagnosis to prognostic and companion diagnostics as well as postoperative monitoring. Diagnose cancer as early as possible, when the disease is easiest to ...
What is early diagnosis? Early diagnosis helps people to plan ahead while they are still able to make important decisions on their care and support needs and on financial and legal ...
based inSan Diego, CALIFORNIA (USA)
At Bionano Genomic, we are committed to unlocking understanding of genome biology to advance the promise of genomics in areas including cancer and human disease, agricultural bioengineering and genome discovery. Our team is not afraid to venture ...
Optical mapping with Genome Imaging using Saphyr reveals what’s missing in your research. Rapidly identify genome variation like never before with the high-throughput Saphyr ...
based inNatick, MASSACHUSETTS (USA)
DYSIS Medical is a medical device company that designs, develops, manufactures and markets imaging systems focusing on the non-invasive, in-vivo detection of cancerous and pre-cancerous lesions. DYSIS Medical has developed a proprietary technology ...
based inParkville, AUSTRALIA
Rhythm Biosciences is interested in developing and commercialising Australian medical diagnostics technology for sale to national and international markets. For Rhythm Biosciences, ColoSTAT is the first proposed product-in-development, intended as ...
The ColoSTAT technology has the potential to become the new, first step screening test for people, who for personal, cultural or clinical reasons, elect to not participate in the existing screening programs for colorectal ...
based inValkenswaard, NETHERLANDS
Established in 2004, 2M Engineering is an esteemed privately-owned SME enterprise renowned for its cutting-edge proficiency in sensors. Our expertise is specifically applied in the domains of wearables, medical devices, and industrial and ...
Driving Innovation Through our comprehensive product creation services; At 2M, we are experts in creating cutting-edge smart sensing solutions that propel innovation in various industries. Our services encompass a wide range of offerings, from ...
based inLondon, UNITED KINGDOM
Getting ahead of cancer is crucial no matter where people are in their cancer journey. From earlier cancer detection to treatment guidance and monitoring, we are helping people get the answers they need to make more informed decisions across the ...
based inVillejuif, FRANCE
Stilla Technologies is the multiplex digital PCR company transforming complex genomic data into actionable insights across a wide range of research and clinical applications including cancer and liquid biopsy studies, cell and gene therapies, ...
based inSeoul, SOUTH KOREA
We make software that transforms medical data into deeper insight. Our AI technology takes medical intelligence to the next level: data-driven medicine. We aim to solve the most critical issues in cancer care today: reduce medical cost and prolong ...
Lunit INSIGHT CXR covers the vast majority of findings. Accurately detects 10 of the most common findings in a chest x-ray. Developed by using Lunit’s cutting-edge deep learning ...
based inMiserey, FRANCE
Innovative Solutions for Cancer Diagnostics. OncoDiag is a French biotechnology company based in Normandy at one hour from Paris and Rouen cities. The company is focused on developing of non-invasive diagnostic tests for early detection of cancers. ...
based inSan Diego, CALIFORNIA (USA)
Nucleix is a liquid biopsy company revolutionizing cancer treatment with earlier disease detection, at a time when intervention can bring the greatest impact for patients. Leveraging PCR-based epigenetics, our pioneering testing approach uses ...
Liquid biopsies are a new powerful tool in cancer diagnostics that is transforming patient healthcare. Body fluids such as blood or urine are obtained from the patient and analyzed for the presence of circulating tumor DNA which is shed from the ...
based inGarching / Munich, GERMANY
ITM Isotope Technologies Munich SE is a privately owned biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes ...
Targeted Radionuclide Therapy (TRT) or Peptide Receptor Radionuclide Therapy (PRRT) is a medical specialty using very small amounts of radioactive compounds, called radiopharmaceuticals, to diagnose and treat various diseases, like cancer. Once ...
based inGeorgetown, TEXAS (USA)
Ezra is focused on early cancer detection through the use of full-body MRI scans. Given that early detection significantly increases survival rates, Ezra's annual Full Body Scans aim to identify cancer signs early, potentially preventing late-stage ...
Ezra offers advanced MRI-based full-body scans aimed at early cancer detection. The service employs 3 Tesla (3T) MRI technology, known for its higher-resolution imaging and superior signal-to-noise ratio, alongside ...
based inMelville, NEW YORK (USA)
FONAR was incorporated in 1978, making it the first, oldest and most experienced MR manufacturer in the industry. FONAR introduced the world's first commercial MRI (a whole-body MRI scanner) in 1980, and went public in 1981. In 1982, FONAR ...